---
title: "Novo Workforce Changes May Signal Ongoing Reset"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283047185.md"
description: "Novo Nordisk is adding around 2,000 employees this year after a significant reset, with 1,400 already hired, including nearly 400 in Denmark. However, the company faces a 5% voluntary attrition rate and an overall turnover of 18% in 2025, indicating that much of the hiring is to fill gaps rather than expand. Last year, Novo ended with about 69,505 employees after cutting 7,800 roles, or 10% of its workforce, during a major restructuring under CEO Mike Doustdar, affecting even senior levels."
datetime: "2026-04-16T19:57:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283047185.md)
  - [en](https://longbridge.com/en/news/283047185.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283047185.md)
---

# Novo Workforce Changes May Signal Ongoing Reset

Novo Nordisk is bringing people back in, adding around 2,000 employees this year after going through a pretty significant reset.

On the surface, it looks like a hiring push, but it is not that simple. According to Bloomberg, about 1,400 of those hires have already joined, including nearly 400 in Denmark. At the same time, people are still leaving. Novo has a 5% voluntary attrition rate, and overall turnover was closer to 18% in 2025, so a lot of this hiring is really about filling gaps rather than growing the team.

That makes more sense when you look at last year. The company ended 2025 with around 69,505 employees, after cutting roughly 7,800 roles, or about 10% of its workforce, during a major restructuring under new CEO Mike Doustdar. Those cuts were not just at the edges either, they reached senior levels, which shows how deep the changes were.

### Related Stocks

- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Key facts: Novo Nordisk early −21.6% 64w; Rexall delivery Canada](https://longbridge.com/en/news/286343869.md)
- [Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial](https://longbridge.com/en/news/286239982.md)
- [Novo’s CEO champions “record-breaking start” for Wegovy pill in US market](https://longbridge.com/en/news/285719519.md)
- [Novo Nordisk Highlights New Wegovy Pill Data](https://longbridge.com/en/news/286293294.md)
- [Novo Nordisk Expands Workforce After Deep Cuts](https://longbridge.com/en/news/283036289.md)